Clinically, they are employed for the treatment of renal cell carcinoma and thyroid cancer,148,149 as well as gastrointestinal stromal tumors and hepatocellular carcinoma.150, 151, 152 Axitinib and nintedanib bind to targets such as VEGFR, PDGFR, and c-KIT. Here, KDR is linked to thyroid gland carcinoma.